SCHEMBL3033403

SCHEMBL3033403

Cc1cccc(C)c1OCc1ccc(N)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.48
MAOA P21397 2/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
SCN4A P35499 10/20 0.47
LMNA P02545 3/20 0.47
SCN1A P35498 2/20 0.47
SCN5A Q14524 2/20 0.47
SCN9A Q15858 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2D6 P10635 2/20 0.47
NFKB1 P19838 2/20 0.47
SCN8A Q9UQD0 2/20 0.47
CYP2C9 P11712 1/20 0.47
TSHR P16473 1/20 0.47
KCNK3 O14649 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18716386 0.82 HTR1A (0.61) MAOBGAAMAPTSMN1; SMN2L3MBTL1
SCHEMBL15329976 0.78 LPL (0.47) MAOAMAPTRAB9AL3MBTL1SCN4A
SCHEMBL3762036 0.78 HTR1A (0.49) MAOBMAOAMAPTL3MBTL1SCN4A
SCHEMBL9362724 0.76 MAOB (0.52) MAOBMAOAGAAMAPTRAB9A
SCHEMBL7697582 0.73 KCNH2 (0.52) MAOASCN4ALMNASCN1ASCN5A
SCHEMBL24726361 0.73 ALDH1A1 (0.59) MAOBMAOAGAAMAPTRAB9A
SCHEMBL29954831 0.73 LIPE (0.62) GAAMAPTSMN1; SMN2L3MBTL1SCN4A
SCHEMBL20631379 0.73 MAPT (0.58) MAOBMAOAGAAMAPTRAB9A
SCHEMBL29958654 0.72 MAOB (0.67) MAOBMAOAGAAMAPTRAB9A
SCHEMBL19612388 0.72 L3MBTL1 (0.67) MAPTL3MBTL1SCN4AHTR1AADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2396316-B1 QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2015-07-01 EP disclosed
US-8937078-B2 Quinazolinones as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-01-20 US disclosed
EP-2396316-A1 QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2011-12-21 EP disclosed
WO-2010093727-A1 QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-08-19 WO disclosed
US-20100204226-A1 QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204226-A1 QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, EGLN3, EGLN2 MAOB 290/4885MAOA 435/4885GAA 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.